Ophthalmology
Partner With Us
Advertisement
Conexiant chevron_right Ophthalmology chevron_right PDS Updates Continue to Reduce Treatment Burden for Patients with nAMD DME and DR
From the Journals

PDS Updates Continue to Reduce Treatment Burden for Patients with nAMD, DME, and DR

These types of improvements are relatively common after initial approval and are the result of optimization as surgical techniques and knowledge evolve.

Conexiant
5 Key Takeaways

  • 1

    The Port Delivery System (PDS) is a refillable implant designed to deliver ranibizumab for treating nAMD, DME, and DR.

  • 2

    Recent updates to the PDS addressed septum dislodgement issues and improved manufacturing processes to enhance device reliability.

  • 3

    The updated PDS received FDA approval in July 2024 and resumed clinical implantation in February 2024.

  • 4

    Clinical trials reported successful refill-exchange procedures with the updated PDS, showing no adverse events in 34 cases.

  • 5

    The PDS is being investigated for new agents like zifibancimig in the phase I/II BURGUNDY trial targeting retinal diseases.

Daily News

Stay up to date with the latest clinical headlines and other information tailored to your specialty.